News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioSpecifics Technologies Corporation (BSTC) Announces Presentations At Upcoming Investor Conferences



2/20/2014 6:17:38 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LYNBROOK, N.Y., Feb. 19, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, today announced that BioSpecifics' President, Tom Wegman, will present at the following upcoming investor conferences.

  • RBC Capital Markets' 2014 Global Healthcare Conference (New York, NY)
    Wednesday, February 26, 2014 at 4:05 p.m. EST
  • Cowen and Company 34th Annual Health Care Conference (Boston, MA)
    Monday, March 3, 2014 at 4:50 p.m. EST
  • ROTH Capital Partners 26th Annual Conference (Laguna Niguel, CA)
    Tuesday, March 11, 2014 at 4:00 p.m. PDT

The live webcasts of these presentations can be accessed under "Events and Presentation" in the Investors section of the Company's website at www.biospecifics.com.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is approved for marketing as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm and for Peyronie's disease in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium). Auxilium is partnered with Actelion Pharmaceuticals Ltd. for the marketing of XIAFLEX in Canada and Australia, and Swedish Orphan Biovitrium AB for the marketing of XIAPEX® (the EU tradename for CCH) in 71 Eurasian and African countries for the treatment of Dupuytren's contracture, and Peyronie's disease pending applicable regulatory approvals. CCH is in clinical development for the treatment of several additional promising indications. Auxilium is testing CCH for frozen shoulder syndrome in a Phase 2b study and also for cellulite in a Phase 2a study. BioSpecifics is currently managing the development of CCH for the treatment of human and canine lipomas. For more information, please visit www.biospecifics.com.

SOURCE BioSpecifics Technologies Corp.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES